v3.26.3
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Total revenues $ 41,962 $ 37,297 $ 117,984 $ 107,380
Total cost of revenues 20,072 20,189 58,717 56,776
Gross profit 21,890 17,108 59,267 50,604
Operating expenses:        
Sales and marketing 8,484 11,848 29,205 35,715
General and administrative 11,675 11,077 36,127 36,364
Research and development 1,190 1,504 3,890 4,918
Total operating expenses 21,349 24,429 69,222 76,997
Income (Loss) from operations 541 (7,321) (9,955) (26,393)
Other (income) expense:        
Interest expense 2,144 2,206 6,535 6,097
Loss on extinguishment of debt     539  
Other income, net (47) (126) (1,229) (561)
Net loss (1,556) (9,401) (15,800) (31,929)
Less: Net gain (loss) attributable to non-controlling interest 136 (356) 121 (89)
Net loss attributable to Neuronetics stockholders $ (1,692) $ (9,045) $ (15,921) $ (31,840)
Net loss per share of common stock outstanding, basic attributable to Neuronetics stockholders (in dollars per share) $ (0.02) $ (0.13) $ (0.22) $ (0.49)
Net loss per share of common stock outstanding, diluted attributable to Neuronetics stockholders (in dollars per share) $ (0.02) $ (0.13) $ (0.22) $ (0.49)
Weighted average common shares outstanding, basic (in shares) 77,004 67,309 73,268 65,006
Weighted average common shares outstanding, diluted (in shares) 77,004 67,309 73,268 65,006
NeuroStar        
Total revenues $ 15,770 $ 15,489 $ 43,372 $ 43,889
Total cost of revenues 3,610 4,607 9,780 12,068
Greenbrook        
Total revenues 26,192 21,808 74,612 63,491
Total cost of revenues $ 16,462 $ 15,582 $ 48,937 $ 44,708